Date and Time: 11.00am – 5.00pm  23rd September 2014

Minutes: Confirmed

Guideline Development Group Meeting: Tuberculosis

Place: NICE offices, Manchester

Present: Andrew Hayward (AH) (Chair)
        Sudy Anaraki (SA)
        Christine Bell (CB)
        Timothy Collyns (TC)
        Michael Eisenhut (ME)
        Mango Hoto (MH)
        Amy McConville (AM)
        Ann Chapman (AC)
        Bertie Squire (BS)
        Horace Reid (HR)

Apologies: Francis Drobniewski (FD)
           Al Story (AS)
           Marc Lipman (ML)
           Uday Katkar (UK)
           Al Story (AS)

In attendance: NICE Staff:
               Michael Heath (MH)
               Lucy Hoppe (LH)
               Margaret Derry (MD)
               Alastair Fischer (AF)
               Rachel Kettle (RK) (pm only)
               Hugh McGuire (HM)
               Chris Gibbons (CG)
               Gabriel Rogers (GR)
               Sue Ellerby (SE)
               Jennifer Wells (JW)
               Mark Jit (MJ) (pm only)
               Peter White (PW) (pm only)
Notes

1. AH welcomed all to the 14th TB GDG meeting. Apologies were noted and the minutes of the last meeting were agreed as an accurate record. The Chair provided a brief overview of the day highlighting the information that would be discussed.

2. All GDG members were asked to share any new conflicts of interest which have not been previously declared. No new conflicts of interest were declared by the group or the NICE team.

3. HM presented the clinical review for the review question: *For people with latent TB infection in which drug resistance is not suspected, which regimen is the most effective in preventing the development of active TB?*

   HM went through the review protocol & search strategy used to inform the questions and all the included evidence. The GDG discussed the evidence available for each regimen and suggested including a statement in the relevant LETR table to explain how GRADE has been used in this situation to provide a ‘low’ grading.

4. GR presented the Health Economic evidence for both the above review question on regimens and also ‘According to their risk factors, which people with latent TB infection should receive drug treatment to prevent the development of active TB?’ The group then went onto deliberate the information.

5. PW & MJ gave an update on the HE modelling for the questions on the treatment of latent TB and asked the group’s advice on a number of points including duration of adverse events - hepatotoxicity and nausea, in response to treatment. The group went onto discuss the information presented and recommended using higher progression rates. It was noted that the model would need to be updated and cost effectiveness estimates refined, before the group could agree recommendations.

6. CG presented the network meta-analysis for both review questions.

7. HM presented the clinical review for the review question: *According to their risk factors, which people with latent TB infection should receive drug treatment to prevent the development of active TB?*

   The GDG discussed the information provided.

8. AH provided a summary of the day and thanked all for their attendance and input.

**Date, time and venue of the next meeting**
10am – 29th and 30th October at the NICE offices in London.